This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TeleFlex Announces Multiple Positive Outcomes on UroLift
by Zacks Equity Research
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.
Teleflex (TFX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of -0.36% and 0.25%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 4.56% and 0.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex's Latest Essential Medical Buyout to Broaden Suite
by Zacks Equity Research
Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
Teleflex (TFX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.49% and -1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Teleflex (TFX) Ahead of Earnings?
by Zacks Equity Research
Teleflex (TFX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.
What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.
Should Pacer Trendpilot US Mid Cap ETF (PTMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PTMC
Should Pacer Trendpilot US Mid Cap ETF (PTMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PTMC
Medical Products Stock Earnings on May 3: BDX, CAH & More
by Zacks Equity Research
Given the solid prospects of the U.S. medical products industry, here we take a look at four major Medical Product companies scheduled to report results on May 3.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.